Compare XOMA & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XOMA | CADL |
|---|---|---|
| Founded | 1981 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.6M | 280.3M |
| IPO Year | N/A | 2021 |
| Metric | XOMA | CADL |
|---|---|---|
| Price | $27.26 | $5.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $60.60 | $19.14 |
| AVG Volume (30 Days) | 110.8K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | $76.93 | N/A |
| Revenue Next Year | $29.28 | N/A |
| P/E Ratio | $29.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.40 | $4.25 |
| 52 Week High | $39.92 | $8.97 |
| Indicator | XOMA | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 46.74 |
| Support Level | $23.92 | $4.57 |
| Resistance Level | $27.70 | $5.42 |
| Average True Range (ATR) | 1.57 | 0.25 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 48.94 | 49.46 |
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.